Treatment of osteoporosis: Role of bone-forming agents

Osteoporosis International

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Reginster, J Y ^a,b,c,d   Halkin, V ^b   Henrotin, Y ^b   Gosset, C ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d Quai Godefroid Kurth 45 (9eme etage)   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; FLUORIDE; GROWTH HORMONE; PARATHYROID HORMONE DERIVATIVE; SOMATOMEDIN; STRONTIUM;

CONFERENCE PAPER; HUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; FEMALE; FLUORIDES; GROWTH HORMONE; HUMANS; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; SOMATOMEDINS; STRONTIUM;

EID: 0032921675     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004167     Document Type: Conference Paper

References (75)

1. Reginster JY. Osteoporose postménopausique: traitement prophylactique. Paris: Masson, 1993.
2. Kaufman JM, Devogelaer JP, Raeman F, et al. Prevention and treatment of postmenopausal osteoporosis: National consensus of the Belgian Bone Club. Clin Rheum 1997;16:343-5.
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
4. Jensen GF, Christiansen C, Transbol I. Fracture frequency and bone preservation in postmenopausal women treated with estrogen. Obstet Gynecol 1982;60:493-6.
5. Liberman U, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
6. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
7. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
8. Reginster JY. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992;13:351-4.
9. Zegels B, Balena R, Eastell R, et al. Effect of risedronate on collagen cross links in postmenopausal osteoporosis. J Bone Miner Res 1995;10(Suppl 1):455.
10. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986;914:1676-84.
11. Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709.
12. Pugsley LI, Selye H. The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J Physiol (Lond) 1993;79:113-7.
13. Podbesek R, Edouard C, Meunier PJ, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 1983;112:1000-5.
14. Canalis E, McCarthy TL, Centrella M. Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis. Endocrinology 1990;126:1806-12.
15. Reeve J. PTH: a future role in the management of osteoporosis? J Bone Miner Res 1996;11:440-5.
16. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ. PTH has a more pronounced effect on vertebral bone mass and biochemical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats. Bone 1994;15:401-8.
17. Sogaard CH, Wronski TJ, McOsker JE, et al. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 1994;134-650-7.
18. Ejersted C, Andreassen TT, Nilsson MHL, et al. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol 1994;130:201-7.
19. Eriksen EF, Melsen F, Mosekilde L. Drug therapy: formation-stimulating regimens. In: Osteoporosis: etiology, diagnosis and management. Philadelphia: Lippincott-Raven, 1995:403-34.
20. Reeve J, Arlot ME, Price TR, et al. Periodic courses of human 1-34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodeling in spinal osteoporosis. Eur J Clin Invest 1987;17:421-8.
21. Slovick DM, Neer RM, Potts JT. Short-term effects of synthetic-human parathyroid hormone (1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 1981;68:1261-71.
22. Finkeistein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
23. Hodsman A, Fraher L, Adachi J. A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone in the treatment of postmenopausal osteoporosis. J Bone Miner Res 1995;10(Suppl);200.
24. Lindsay R, Cosman F, Shen V, et al. Bone mass increments induced by PTH treatment can be maintained by estrogen. J Bone Miner Res 1995;10(Suppl);200.
25. Cohen FE, Strewler GJ, Bradley S, et al. Analogs of parathyroid hormone modified at positions 3 and 6. J Biol Chem 1991;266:1997-2004.
26. Lane NE, Kimmel DB, Nilsson MHL, et al. Bone-selective analogs of human PTH (1-34) increase bone formation in ovariectomized rat model. J Bone Miner Res 1996;1:614-25.
27. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465-74.
28. Reifenstein EC, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 1947;26:24-56.
29. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol 1985;10:11-8.
30. Taggart HA, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanazolol) therapy for postmenopausal osteoporosis. Metabolism 1982; 3:1147-52.
31. Ishak KG, Zimmerman HJ. Hepatotoxic effects or the anabolic/ androgenic steroids. Semin Liver Dis 1987;7:230-6.
32. Wilson J, Griffin JE. The use and misuse of androgens. Metabolism 1980;29:1278-95.
33. Geusens P. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Clin Rheum 1995;14:32-9.
34. Kasperck CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989;124:1576-8.
35. Riggs BL. Formation-stimulating regimens other than sodium fluoride. Am J Med 1993;95:62-8.
36. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986;1:347-57.
37. Hassager C, Podenphant J, Riis BJ, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 1989;38:238-42.
38. Need AG, Horowitz M, Morris HA, et al. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis. Clin Orthop 1987;225:273-8.
39. 3, or intermittent calcium infusions. Maturitas 1986;8:281-9.
40. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Bone Miner J 1992;305:1124-8.
41. Shore RM, Chesney RW, Mazess RB, et al. Bone mineral status in growth hormone deficiency. J Pediatr 1980;96:393-6.
42. Marie PJ, Garbat MT, Hott M, et al. Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 1985;11:5-13.
43. Marie PJ, Hott M. Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 1986;35:547-51.
44. Grynpas MD, Hamilton E, Cheung R, et al. Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone 1996;18:253-9.
45. Boivin G, Deloffre P, Perrat B, et al. Strontium (Sr) distribution and interreactions with bone mineral in male monkey iliac bone after strontium salt (S-12911) administration. Osteoporos Int 1996;6:251.
46. Amman P, Rizzoli R, Deloffre P, et al. The increase in vertebral bone mass induced in intact rats by long-term administration of the strontium salt S-12911 is directly correlated with vertebral bone strength. Osteoporos Int 1996;6:259.
47. Meunier PJ, Slosman D, Delmas PD, et al. The strontium salt S-12911: a new candidate for the treatment of osteoporosis. Osteoporos Int 1996;6:241.
48. Kaufman JM, Taelman P, Vermeulen A, et al. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1993;74:118-23.
49. Demuinck Keizer-Schrama S, Rikken B, Wynne HJ, et al. Dose-response study of biosynthetic hGH in GH deficient children. J Clin Endocrinol Metab 1992;74:898-905.
50. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
51. Brixen K, Nielsen HK, Mosekilde L, et al. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609-18.
52. Kelijman M. Age-related alterations of the GH/IGF-I axis. J Am Geriatr Soc 1991;39:295-307.
53. Rosen CJ, Donahue LR, Hunter SJ. Age-related changes in insulin-like growth factor binding proteins. J Clin Endocrinol Metab 1990;71:575-9.
54. Johansson AG, Lindh E, Ljunghall S. Insulin-like growth factor stimulates bone turnover in osteoporosis. Lancet 1992;339:1619.
55. Aloia JF, Zanz I, Ellis K, et al. Effects of GH in osteoporosis. J Clin Endocrinol Metab 1976;43:992-9.
56. Aloia JF, Vaswani A, Meunier PJ, et al. Coherence treatment of postmenopausal osteoporosis with GH and calcitonin. Calcif Tissue Int 1987;40:253-9.
57. Johannson AG, Lindh E, Blum WF, et al. Effects of short-term treatment with IGF-1 and GH on markers of bone metabolism in idiopathic osteoporosis. J Bone Miner Res 1994;9:328.
58. Ebeling PR, Jones JD, O'Fallon WM, et al. Short term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 1993;77:1384-7.
59. Mohan S, Bautista CM, Wergedal J, et al. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci USA 1989;86:8338-42.
60. Nasurawa K, Nakaruma T, Suzuki K, et al. The effects of recombinant human insulin-like growth factor (rhIFG)-1 and rhIFG-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res 1995;10:1853-64.
61. Cohen P. Fluoride and calcium therapy by myeloma bone lesions. JAMA 1966;198:583-586.
62. Bellows CG, Heersche JNM, Aubin JE. The effects of fluoride on osteoblast progenitors in vitro. J Bone Miner Res 1990;5:101-5.
63. Farley JR, Tarbaux N, Hall S, et al. Mitogenic action(s) of fluoride on osteoblastline cells, determinants of the response in vitro. J Bone Miner Res 1990;5:107-13.
64. Kanis J. Treatment of symptomatic osteoporosis with fluoride. Am J Med 1993;95:53-61.
65. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
66. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as treatment for postmenopausal osteoporosis. Osteoporos Int 1991;1:155-61.
67. Reginster JY, Meurmans L, Zegels B, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. Ann Intern Med 1998;129:1-8.
68. Mamelle N, Meunier PJ, Dusan R, et al. Risk-benefit ratio in sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;II:361-5.
69. Pak CY, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995;123:401-8.
70. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom P, Netter G. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study. Osteoporos Int 1998;8:4-12.
71. Saltman PD, Strause LG. The role of trace minerals in osteoporosis. J Am Coll Nutr 1993;12:384-9.
72. Reginster JY, Roux C, Riis BJ. Design for IMEFS (Ipriflavone Multicentre European Fracture Study). Osteoporos Int 1996;6(Suppl 1):318.
73. Biquet I, Collette J, Dauphin JF, et al. Prevention of postmenopausal bone loss by administration of boron. Osteoporos Int 1996;6:249.
74. Keeting PE, Oursler MJ, Wiegand KE, et al. Zeolite A increases proliferation, differentiation, and transforming growth factor beta production in normal adult human osteoblast-like cells in vitro. J Bone Miner Res 1992;7:1281-9.
75. Franchimont N, Franchimont P, Gaspar S, et al. Organic silicon decreases interleukin 6 but not leukemia inhibiting factor production in human osteoblast like cells in vitro. Bone 1995:16:226.